These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37932437)

  • 1. Trends in rare disease drug development.
    Chen R; Liu S; Han J; Zhou S; Liu Y; Chen X; Zhang S
    Nat Rev Drug Discov; 2024 Mar; 23(3):168-169. PubMed ID: 37932437
    [No Abstract]   [Full Text] [Related]  

  • 2. Orphan drug development in China: progress and challenges.
    Zhang S; Chen L; Zhang Z; Zhao Y
    Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
    [No Abstract]   [Full Text] [Related]  

  • 3. Patients left behind: Rare dermatologic conditions miss the orphan drug development boom.
    Chavez A; Licholai G; Murrell DF
    J Am Acad Dermatol; 2019 Oct; 81(4):1025-1026. PubMed ID: 30880063
    [No Abstract]   [Full Text] [Related]  

  • 4. Defining orphan conditions in the context of the European orphan regulation: challenges and evolution.
    O'Connor DJ; Sheean ME; Hofer MP; Tsigkos S; Mariz S; Fregonese L; Larsson K; Hivert V; Westermark K; Naumann-Winter F; Stoyanova-Beninska V; Barišić I; Capovilla G; Magrelli A; Sepodes B
    Nat Rev Drug Discov; 2019 Jul; 18(7):479-480. PubMed ID: 30940922
    [No Abstract]   [Full Text] [Related]  

  • 5. Flexibility in the FDA approach to orphan drug development.
    Hunter NL; Rao GR; Sherman RE
    Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving the Study of New Medicines for Children With Rare Diseases.
    Bourgeois FT; Hwang TJ
    JAMA Pediatr; 2018 Jan; 172(1):7-9. PubMed ID: 29131900
    [No Abstract]   [Full Text] [Related]  

  • 7. Reforming the Orphan Drug Act for the 21st Century.
    Sarpatwari A; Kesselheim AS
    N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
    [No Abstract]   [Full Text] [Related]  

  • 8. Orphan drug designation and development in Japan: 25 years of experience and assessment.
    Sakushima K; Takeda H; Aoi Y
    Nat Rev Drug Discov; 2021 Dec; 20(12):893-894. PubMed ID: 33723413
    [No Abstract]   [Full Text] [Related]  

  • 9. Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals.
    Miller KL; Lanthier M
    Health Aff (Millwood); 2024 Jan; 43(1):18-26. PubMed ID: 38190603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and trend of clinical development of orphan drugs in China.
    Xiang Z; Jiang W; Yan B; Jiang J; Zheng H
    Orphanet J Rare Dis; 2022 Jul; 17(1):294. PubMed ID: 35897012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases.
    Duarte DM; Beatriz da Silva Lima M; Sepodes B
    Regul Toxicol Pharmacol; 2020 Dec; 118():104810. PubMed ID: 33122047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.
    Jayasundara K; Hollis A; Krahn M; Mamdani M; Hoch JS; Grootendorst P
    Orphanet J Rare Dis; 2019 Jan; 14(1):12. PubMed ID: 30630499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Orphan Drug Framework (ODF) for Canada.
    Lee DK; Wong B
    J Popul Ther Clin Pharmacol; 2014; 21(1):e42-6. PubMed ID: 24671833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
    Micallef J; Blin O
    Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.
    Tambuyzer E; Vandendriessche B; Austin CP; Brooks PJ; Larsson K; Miller Needleman KI; Valentine J; Davies K; Groft SC; Preti R; Oprea TI; Prunotto M
    Nat Rev Drug Discov; 2020 Feb; 19(2):93-111. PubMed ID: 31836861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Development for Rare Paediatric Epilepsies: Current State and Future Directions.
    Auvin S; Avbersek A; Bast T; Chiron C; Guerrini R; Kaminski RM; Lagae L; Muglia P; Cross JH
    Drugs; 2019 Dec; 79(18):1917-1935. PubMed ID: 31734883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook.
    Hechtelt Jonker A; Hivert V; Gabaldo M; Batista L; O'Connor D; Aartsma-Rus A; Day S; Sakushima K; Ardigo D
    Nat Rev Drug Discov; 2020 Aug; 19(8):495-496. PubMed ID: 32313251
    [No Abstract]   [Full Text] [Related]  

  • 19. How to START? Four pillars to optimally begin your orphan drug development.
    Jonker AH; Batista L; Gabaldo M; Hivert V; Ardigo D;
    Orphanet J Rare Dis; 2023 Aug; 18(1):229. PubMed ID: 37537670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One drug to treat many diseases: unlocking the economic trap of rare diseases.
    Pierzynowska K; Kamińska T; Węgrzyn G
    Metab Brain Dis; 2020 Dec; 35(8):1237-1240. PubMed ID: 32926291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.